The pandemic changed the way we lived our lives, and regulatory agencies were no exception to that rule.
In early March 2020, the US Food and Drug Administration (FDA) announced it was postponing most inspections outside the United States.
However, by the end of 2020, FDA and the European Directorate for the Quality of Medicines & HealthCare (EDQM) had managed to complete over 2,200 inspections across the world.
The FDA was the most active locally, and issued almost 40 warning letters to drug manufacturers based in the US. Consistent with the previous years’ trend, warning letters in the US were followed by those issued to manufacturers in India (13) and China (7)....[PharmaCompass]